Skip to main content

Pediculosis Capitis

3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Alliance Pharmaceuticals
1 program
1
Vamousse Spray 'n' GoPhase 41 trial
Active Trials
NCT05565820Completed58Est. Mar 2023
ParaPRO
ParaPROIN - Carmel
2 programs
2
NatrOVA Creme Rinse - 1%Phase 21 trial
Spinosad Creme Rinse - Vehicle ControlPhase 21 trial
Active Trials
NCT00857935Completed24Est. Apr 2007
NCT00858481Completed36Est. Nov 2005

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Alliance PharmaceuticalsVamousse Spray 'n' Go
ParaPRONatrOVA Creme Rinse - 1%
ParaPROSpinosad Creme Rinse - Vehicle Control

Clinical Trials (3)

Total enrollment: 118 patients across 3 trials

A Study to Evaluate the Efficacy and Safety of a Leave-in Spray in Subjects With Head Lice Infestation

Start: Dec 2022Est. completion: Mar 202358 patients
Phase 4Completed
NCT00857935ParaPRONatrOVA Creme Rinse - 1%

A Safety and Efficacy Pilot Study Comparing NatrOVA Creme Rinse 1% and NIX Creme Rinse

Start: Mar 2007Est. completion: Apr 200724 patients
Phase 2Completed
NCT00858481ParaPROSpinosad Creme Rinse - Vehicle Control

A Pilot Dose Ranging Study of Spinosad Creme Rinse

Start: Sep 2005Est. completion: Nov 200536 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.